Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Good Life Plus

    MCap

    GBP12m

    Last close

    GBP0.02

    ▲ 0.40 (22.86%)

    KEFI Gold and Copper

    MCap

    GBP39m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    OSE Immunotherapeutics

    MCap

    EUR132m

    Last close

    EUR6.14

    ▲ 0.68 (12.45%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Amoeba (PAR: ALMIB)

Last close As at 02/07/2024

EUR0.42

— 0.00 (−0.48%)

Market capitalisation

EUR21m

Amoéba is developing biological fungicides for treating diseases such as mildews and rusts, which have a major economic impact on the production globally of a wide range of crops. These novel fungicides are based on the characteristics of the Willaertia magna C2c Maky amoeba.

P&S Intelligence’s report noted that the global biocontrol agents market was worth c $4.9bn in 2021 and predicted it would increase to $13.6bn by 2030. According to McKinsey, the global skincare market was $200bn in 2022 and is expected to expand at a CAGR of 6% from 2022 to 2027. There are clear trends towards natural ingredients and premium products, with McKinsey forecasting that the premium end of the market should grow at an 8% CAGR, compared with 5% for the mass market and 6% for the global market. This trend should represent a significant tailwind to any Amoéba product sourced from a natural spring in the south of France.

Latest Insights

View More

Industrials | Outlook

Amoeba — Focused on high-value opportunities

Industrials | Update

Amoeba — Biocontrol plant paves path to commercialisation

Industrials | Update

Amoeba — Scaling up for commercialisation

Industrials | Update

Amoeba — Building on an exceptional year
Visit Website

Sector

Industrials

Equity Analyst

Analyst avatar placeholder

Key Management

  • Benoit Villers

    Chairman

  • Jean-Francois Doucet

    CEO

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (12.9) 1.0 (28.3)
Relative (7.1) 8.6 (31.8)
52 week high/low €0.7/€0.4

Financials

FY23 grant income was €0.2m higher year-on-year, which was more than offset by a surge in operating costs of €1m to €7.3m, resulting in a widening of the EBIT loss by €0.8m to €6.6m. At end-FY23, Amoéba had €0.5m cash (€5.5m end-FY22) on its balance sheet and €4.9m debt (€2.4m end-FY22). The company is fully funded through CY24 via an existing debt facility with its lead shareholder. Amoéba expects to generate first revenues in 2026 and can meet early demand from existing production capacity.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 0.0 (4.7) (7.7) (22.99) N/A N/A
2023A 0.0 (5.6) (6.9) (14.10) N/A N/A
2024E 0.0 (5.5) (6.6) (13.33) N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Update

Industrials

Amoeba — Biocontrol plant paves path to commercialisation

Update

Industrials

Amoeba — Scaling up for commercialisation

Industrials

Outlook

Amoeba — Focused on high-value opportunities

Update

Industrials

Amoeba — Building on an exceptional year

edison tv

Industrials

Amoeba – executive interview

Initiation

Industrials

Amoeba — Fighting pathogens, respecting nature

Thematics

thematic

Industrials

Deutsches Eigenkapitalforum (EKF) 2023 industrials

thematic

Industrials

The long and winding road

thematic

Industrials

Quantum computing: A booming industry

thematic

Industrials

UK housebuilders
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free